Page 2058 - Williams Hematology ( PDFDrive )

2032 Part XII: Hemostasis and Thrombosis Chapter 118: Heparin-induced Thrombocytopenia 2033

19. Smythe M, Koerber JM, Mattson JC: The incidence of recognized heparin-induced 50. Oliveira GB, Crespo EM, Becker RC, et al: Complications After Thrombocytopenia
thrombocytopenia in a large, tertiary care teaching hospital. Chest 131:1644, 2007. Caused by Heparin (CATCH) Registry Investigators: Incidence and prognostic signif-
20. Muslimani AA, Ricaurte B, Daw HA: Immune heparin-induced thrombocytopenia result- icance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch
ing from preceding exposure to heparin catheter flushes. Am J Hematol 82:652, 2007. Intern Med 168:94, 2008.
21. Laster J, Silver D: Heparin-coated catheters and heparin-induced thrombocytopenia. J 51. Warkentin TE, Kelton JG: Delayed-onset heparin-induced thrombocytopenia and
Vasc Surg 7:667, 1988. thrombosis. Ann Intern Med 135:502, 2001.
22. Juhl D, Eichler P, Lubenow N, et al: Incidence and clinical significance of anti-PF4/ 52. Rice L, Attisha WK, Drexler A, Francis JL: Delayed-onset heparin-induced thrombocy-
heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples topenia. Ann Intern Med 136:210, 2002.
referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 53. Warkentin TE, Basciano PA, Knopman J, Bernstein RA: Spontaneous heparin-induced
76:420, 2006. thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder.
23. Warkentin TE, Kelton JG: Temporal aspects of heparin-induced thrombocytopenia. N Blood 123:3651, 2014.
Engl J Med 344:1286, 2001. 54. Warkentin TE: Clinical presentation of heparin-induced thrombocytopenia. Semin
24. Krauel K, Pötschke C, Weber C, et al: Platelet factor 4 binds to bacteria, [corrected] Hematol 35:9, 1998.
inducing antibodies cross-reacting with the major antigen in heparin-induced throm- 55. Warkentin TE, Roberts RS, Hirsh J, Kelton JG: An improved definition of immune
bocytopenia. Blood 117:1370, 2011. heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern
25. Zheng Y, Yu M, Podd A, et al: Critical role for mouse marginal zone B cells in PF4/ Med 163:2518, 2003.
heparin antibody production. Blood 121:3484, 2013. 56. Greinacher A, Farner B, Kroll H, et al: Clinical features of heparin-induced thrombocy-
26. Zhang X, Chen L, Bancroft DP, et al: Crystal structure of recombinant human platelet topenia including risk factors for thrombosis. A retrospective analysis of 408 patients.
factor 4. Biochemistry 33:8361, 1994. Thromb Haemost 94:132, 2005.
27. Stuckey JA, St Charles R, Edwards BF: A model of the platelet factor 4 complex with 57. Warkentin TE, Kelton JG: A 14-year study of heparin-induced thrombocytopenia. Am
heparin. Proteins 14:277, 1992. J Med 101:502, 1996.
28. Li ZQ, Liu W, Park KS, et al: Defining a second epitope for heparin-induced throm- 58. Hong AP, Cook DJ, Sigouin CS, Warkentin TE: Central venous catheters and upper-
bocytopenia antibodies using KKO, a murine HIT-like monoclonal antibody. Blood extremity deep-vein thrombosis complicating immune heparin-induced thrombocy-
99:1230, 2002. topenia. Blood 101:3049, 2003.
29. Litvinov RI, Yarovoi SV, Rauova L, et al: Distinct specificity and single-molecule kinet- 59. Warkentin TE, Levine MN, Hirsh J, et al: Heparin-induced thrombocytopenia in
ics characterize the interaction of pathogenic and non-pathogenic antibodies against patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl
platelet factor 4-heparin complexes with platelet factor 4. J Biol Chem 288:33060, 2013. J Med 332:1330, 1995.
30. Greinacher A, Pötzsch B, Amiral J, et al: Heparin-associated thrombocytopenia: Isola- 60. Warkentin TE, Roberts RS, Hirsh J, Kelton JG: Heparin-induced skin lesions and
tion of the antibody and characterization of a multimolecular PF4-heparin complex as other unusual sequelae of the heparin-induced thrombocytopenia syndrome: A nested
the major antigen. Thromb Haemost 71:247, 1994. cohort study. Chest 127:1857, 2005.
31. Horne MK 3rd, Alkins BR: Platelet binding of IgG from patients with heparin-induced 61. Warkentin TE, Greinacher A: Heparin-induced anaphylactic and anaphylactoid reac-
thrombocytopenia. J Lab Clin Med 127:435, 1996. tions: Two distinct but overlapping syndromes. Expert Opin Drug Saf 8:129, 2009.
32. Rauova L, Poncz M, McKenzie SE, et al: Ultralarge complexes of PF4 and heparin are 62. Schindewolf M, Kroll H, Ackermann H, et al: Heparin-induced non-necrotizing skin
central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105:131, 2005. lesions: Rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost
33. Suvarna S, Espinasse B, Qi R, et al: Determinants of PF4/heparin immunogenicity. 8:1486, 2010.
Blood 110:4253, 2007. 63. Cuker A, Cines DB: How I treat heparin-induced thrombocytopenia. Blood 119:2209, 2012.
34. Reilly MP, Taylor SM, Hartman NK, et al: Heparin-induced thrombocytopenia/throm- 64. Lo GK, Juhl D, Warkentin TE, et al: Evaluation of pretest clinical score (4 T’s) for the
bosis in a transgenic mouse model requires human platelet factor 4 and platelet activa- diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Hae-
tion through FcγRIIA. Blood 98:2442, 2001. most 4:759, 2006.
35. Rauova L, Zhai L, Kowalska MA, et al: Role of platelet surface PF4 antigenic complexes 65. Cuker A, Gimotty PA, Crowther MA, Warkentin TE: Predictive value of the 4Ts scoring
in heparin-induced thrombocytopenia pathogenesis: Diagnostic and therapeutic system for heparin-induced thrombocytopenia: A systematic review and meta-analysis.
implications. Blood 107:2346, 2006. Blood 120:4160, 2012.
36. Warkentin TE, Hayward CP, Boshkov LK, et al: Sera from patients with heparin- 66. Nagler M, Fabbro T, Wuillemin WA: Prospective evaluation of the interobserver reli-
induced thrombocytopenia generate platelet-derived microparticles with procoagulant ability of the 4Ts score in patients with suspected heparin-induced thrombocytopenia.
activity: An explanation for the thrombotic complications of heparin-induced throm- J Thromb Haemost 10:151, 2012.
bocytopenia. Blood 84:3691, 1994. 67. Cuker A, Arepally G, Crowther MA, et al: The HIT Expert Probability (HEP) Score:
37. Visentin GP, Malik M, Cyganiak KA, Aster RH: Patients treated with unfractionated A novel pre-test probability model for heparin-induced thrombocytopenia based on
heparin during open heart surgery are at high risk to form antibodies reactive with broad expert opinion. J Thromb Haemost 8:2642, 2010.
heparin:platelet factor 4 complexes. J Lab Clin Med 128:376, 1996. 68. Bakchoul T, Giptner A, Najaoui A, et al: Prospective evaluation of PF4/heparin
38. Pouplard C, Iochmann S, Renard B, et al: Induction of monocyte tissue factor expres- immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Hae-
sion by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced most 7:1260, 2009.
thrombocytopenia. Blood 97:3300, 2001. 69. Lo GK, Sigouin CS, Warkentin TE: What is the potential for overdiagnosis of heparin-
39. Arepally GM, Mayer IM: Antibodies from patients with heparin-induced thrombo- induced thrombocytopenia? Am J Hematol 82:1037, 2007.
cytopenia stimulate monocytic cells to express tissue factor and secret interleukin-8. 70. Greinacher A, Juhl D, Strobel U, et al: Heparin-induced thrombocytopenia: A prospective
Blood 98:1252, 2001. study on the incidence, platelet-activating capacity and clinical significance of antiplatelet
40. Xiao Z, Visentin GP, Dayananda KM, Neelaegham S: Immune complexes formed fol- factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 5:1666, 2007.
lowing the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate 71. Pauzner R, Greinacher A, Selleng K, et al: False-positive tests for heparin-induced
human neutrophil activation and cell adhesion. Blood 112:1091, 2008. thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus
41. Kasthuri RS, Glover SL, Jonas W, et al: PF4/heparin-antibody complex induces mono- erythematosus. J Thromb Haemost 7:1070, 2009.
cyte tissue factor expression and release of tissue factor positive microparticles by acti- 72. Sikara MP, Routsias JG, Samiotaki M, et al: β2 Glycoprotein I (β2GPI) binds platelet
vation of FcγRI. Blood 119:5285, 2012. factor 4 (PF4): Implications for the pathogenesis of antiphospholipid syndrome. Blood
42. Ward JV, Packham MA: Characterization of the sulfated glycosaminoglycans on the sur- 115:713, 2010.
face and in the storage granules of rabbit platelets. Biochim Biophys Acta 583:196, 1979. 73. Zwicker JI, Uhl L, Huang WY, et al: Thrombosis and ELISA optical density values in
43. Handin RI, Cohen HJ: Purification and binding properties of human platelet factor hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost
four. J Biol Chem 251:4273, 1976. 2:2133, 2004.
44. Rauova L, Hirsch JD, Greene TK, et al: Monocyte-bound PF4 in the pathogenesis of 74. Warkentin TE, Sheppard JI, Moore JC, et al: Quantitative interpretation of optical density
heparin-induced thrombocytopenia. Blood 116:5021, 2010. measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 6:1304,
45. Carlsson LE, Lubenow N, Blumentritt C, et al: Platelet receptor and clotting factor 2008.
polymorphisms as genetic risk factors for thromboembolic complications in heparin- 75. Raschke RA, Curry SC, Warkentin TE, Gerkin RD: Improving clinical interpretation of
induced thrombocytopenia. Pharmacogenetics 13:253, 2003. the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis
46. Arepally G, McKenzie SE, Jiang XM, et al: Fc gamma RIIA H/R 131 polymorphism, of heparin-induced thrombocytopenia through the use of receiver operating characteris-
subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in tic analysis, stratum-specific likelihood ratios, and Bayes theorem. Chest 144:1269, 2013.
patients with heparin-induced thrombocytopenia and thrombosis. Blood 89:370, 1997. 76. Cuker A, Ortel TL: ASH evidence-based guidelines: Is the IgG-specific anti-PF4/hep-
47. Carlsson LE, Santoso S, Baurichter G, et al: Heparin-induced thrombocytopenia: New arin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?
insights into the impact of the FcgammaRIIa-R-H131 polymorphism. Blood 92:1526, 1998. Hematology Am Soc Hematol Educ Program 2009:250, 2009.
48. Chong BH, Pilgrim RL, Cooley MA, Chesterman CN: Increased expression of platelet 77. Whitlatch NL, Kong DF, Metjian AD, et al: Validation of the high-dose heparin confirma-
IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood 81:988, 1993. tory step for the diagnosis of heparin-induced thrombocytopenia. Blood 116:1761, 2010.
49. Cuker A, Rauova L, Bolgiano D, et al: Atherosclerosis is not a risk factor for anti-platelet 78. Warkentin TE, Sheppard JI: No significant improvement in diagnostic specificity of an
factor 4/heparin antibody formation after cardiopulmonary bypass surgery. Thromb anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J
Haemost 111:1191, 2014. Thromb Haemost 4:281, 2006.

Kaushansky_chapter 118_p2025-2034.indd 2033 9/18/15 5:43 PM